… a series of events activating the host’s own immune system. (… the migration of the
nanoparticles into LNs and their … to enhance the antitumor immunity of in situ cancer vaccines. …

… unique capability to initiate precise anti-tumor immune responses and establish enduring …
-pairing-triggered aggregation, we demonstrate the occurrence of nanoparticle aggregation …

… NP-based DC vaccines may accumulate in lymph node DCs … and that trigger a Th1-type
immune response to promote host … vaccines and therapeutics that can better prevent and target …

… prophylactic antitumor immunities. Specifically, therapeutic … To further develop lymph
node-targeted delivery of vaccines … synthesized mannose-grafted polymeric nanoparticles to target …

… It can systematically target both primary tumor cells as well as secondary … immune cells in
lymphoid tissues and antitumor immune cells in tumor microenvironment (TME) are triggered to …

… that realize more effective activation of antitumor immunity. … The ICD process can be
triggered by a series of antitumor … Silica nanoparticles have been used to target lymph nodes …

… a “self-adjuvant” by targeting draining lymph node (DLN) and … enhance anti-tumor immunity,
while heterocyclic lipids in the cytoplasm induces the production of type I IFN via activating …

… A primary goal of cancer immunotherapy is to break immune … of the Ad5-TRP2 vaccine to
trigger a detectable TRP2-specific … to traffic to the lymph nodes and interact with immune cell …

… -II molecules and migrate to the lymph nodes (LNs) for specific T … antigens are likely to trigger
a more effective anti-tumor immune … By introducing the targeting ability of exogenous and …

… Activating humoral and cellular immunity in lymph nodes (… demonstrated to contribute to
antitumor immunity. The results … as the most important targets for cancer vaccine delivery 31 , …